



the business of Bio & Health Sciences
BioSpectrum

24 years of leveraging the business of Bio & Health Sciences
www.biospectrumindia.com

BIOSPECTRUM INDIA

Editorial Calendar

2027

India first. Benchmarked to North America and Europe.

12

monthly main
themes

24

sponsor-ready
whitepapers

24

industry reports,
India and global

24

special newsletter
editions

24

sponsorable
technology webinars

HOW 2027 IS BUILT

Five content streams, one calendar

BioSpectrum India keeps India at the centre of every issue, then adds a Western lens, alternating North America and Europe to match where the month's news is coming from. Every theme carries its own whitepapers, reports, special newsletters and webinars, so partners can plan a year of visibility around the conversations that matter most to their buyers.

- 01 One main theme a month** Every issue is built around a single big question for Indian life sciences, timed to the policy, conference and deal calendar our readers already follow.
- 02 Two whitepapers every month** Twenty-four whitepaper topics, each designed so one technology or service partner can own the argument with editorial credibility.
- 03 Industry reports: India plus the world** Each month pairs an India market report with a global report on North America or Europe, so Indian readers see the benchmark and international readers see the India opportunity.
- 04 Two special newsletters a month** Themed special editions sent to the full BioSpectrum India subscriber base, many timed to the conferences and events that set the month's agenda.
- 05 24 sponsorable webinars** A standing bank of technology webinars, two slotted against each month's theme, built for partners who want qualified leads as well as visibility.

QUARTERLY ARCS

Q1 Policy and Platforms Execution, bioeconomy policy and the biosimilar opportunity.	Q2 Pipelines and Patients Vaccines and immunisation, clinical research and India-origin innovation reaching global deal tables.	Q3 Precision and Production Diagnostics and genomics, biologics manufacturing and digitisation, cell and gene therapy.	Q4 Power Shifts Rare cancer access, the pharma supply chain reset and the 2028 agenda.
--	---	--	--

YEAR AT A GLANCE

2027 in one table

MONTH	MAIN THEME	WHITEPAPERS	INDUSTRY REPORTS	SPECIAL NEWSLETTERS
JAN	India BioPharma 2027: The Execution Year	WP1 CRDMO India 2027: Winning Western Programmes in a Supply Chain Reset WP2 The R&D Case for Budget 2027-28	India India CRDMO and CDMO Landscape Report 2027 North America US Biopharma Outsourcing Outlook 2027	JPM Week Dispatch CRDMO Capacity Watch
FEB	Bioeconomy and the Policy Engine	WP1 BioE3 in Motion: From Policy Framework to Operating Biomanufacturing Hubs WP2 Selling into a Reformed Europe: A Market Access Playbook for Indian Pharma	India State Life Sciences Policy Scorecard 2027 Europe Europe Generics and Biosimilars Market Access Report 2027	Budget Decoded State Policy Tracker
MAR	Biosimilars and Biologics: India's Next Export Engine	WP1 Intensified Bioprocessing for Biosimilars: Lower Cost of Goods at Global Quality WP2 Comparability First: Building Biosimilar Dossiers Around Analytics	India India Biosimilars Pipeline Report 2027 North America US Biosimilar Market Access and Interchangeability Outlook	Biosimilar Launch Radar Bioprocess Tech Brief
APR	Vaccines and the National Immunisation Programme	WP1 Rapid-Response Vaccine Platforms: Building mRNA and LNP Capability in India WP2 Fill-Finish at Global Standard: Annex 1 Readiness for Indian Sterile Manufacturers	India India Vaccine Manufacturing and Export Report 2027 Europe Europe Pandemic Preparedness and Vaccine Procurement Report	Vaccine Supply Watch Sterile Manufacturing Brief
MAY	Clinical Research India: Speed, Scale and Site Quality	WP1 ICH E6(R3) in Practice: Risk-Based Quality Management for Indian Trial Sites WP2 Hybrid and Decentralised Trials in India: Technology, Data Integrity and Patient Access	India India Clinical Trials Landscape Report 2027 North America US Sponsor Site Selection Survey: Asia-Pacific and India	Trial Tracker India ASCO Preview
JUN	Made-in-India Innovation: From Molecule to Global Deal	WP1 Out-Licensing from India: Structuring Deals Western Partners Will Sign WP2 AI in Drug Discovery: From Platform Claims to Validated Pipelines	India India BioPharma Deals and Out-Licensing Tracker: H1 2027 North America North America Biotech Funding and Licensing Report: H1 2027	India at BIO 2027 Deal Desk: H1 2027
JUL	Diagnostics, Genomics and Precision Medicine	WP1 Population Genomics to Clinical Practice: Lessons from GenomeIndia WP2 Molecular Diagnostics Beyond the Metros: Point-of-Care Platforms for Tier-2 and Tier-3 India	India India IVD and Genomics Market Report 2027 Europe Europe IVDR Readiness and Market Entry Report	Genomics Brief Lab to Market
AUG	Biologics Manufacturing and Digitisation	WP1 Revised Schedule M: Closing the GMP Gap for Mid-Sized Manufacturers WP2 Digital Twins and PAT: Data-Driven Control for Pharma and Bioprocessing	India India Pharma Quality and Compliance Report 2027 North America US Onshoring and Tariff Impact Report for Indian Exporters	Quality Watch Smart Plant Brief
SEP	Cell and Gene Therapy: Addressing the Challenges	WP1 Point-of-Care CAR-T: Decentralised Manufacturing Models for India WP2 Viral Vector Supply for India: Build, Buy or Partner	India India Cell and Gene Therapy Pipeline Report 2027 Europe Europe ATMP Market and Partnering Report	CGT Special Edition ATMP Europe Brief
OCT	Rare Cancers and the Access Question	WP1 Access Models for Innovative Oncology in India WP2 ADCs and Complex Oncology Manufacturing: India's Opportunity	India India Oncology and Rare Disease Access Report 2027 North America + Europe Transatlantic Drug Pricing Reform Report	ESMO Special Access Watch
NOV	Indian Pharma in the Western Supply Chain Reset	WP1 China+1 to India First: De-Risking API and KSM Supply for US and EU Buyers WP2 Temperature-Controlled Logistics for Biologics and Advanced Therapies	India India API and KSM Self-Reliance Report 2027 Europe Europe Security-of-Supply and Sourcing Report	CPHI India Special Supply Chain Monitor
DEC	The Road to 2028: AI, Talent and the Leaders of 2027	WP1 AI Across the Life Sciences Value Chain: A 2028 Readiness Playbook WP2 Talent 2028: Skilling India's Bioeconomy Workforce	India BioSpectrum India Annual Industry Scorecard 2027 North America + Europe Western Pharma Outlook 2028: Demand, Pricing and Partnering	Year in Review 2027 2028 Outlook

01

JANUARY 2027 Q1 · Policy and Platforms

India BioPharma 2027: The Execution Year

After two years of policy announcements, 2027 is the year India's bioeconomy has to show delivered capacity, closed deals and approved products. We open the year by asking who is ready.

Calendar hooks: J.P. Morgan Healthcare Conference, San Francisco (January); run-up to Union Budget 2027-28

COVER STORY

The Execution Year: 27 CEOs on what India's life sciences industry must deliver in 2027

Story focus: Top domestic players across pharma, biopharma, diagnostics, bioservices, technology and biosuppliers.

India lens. CRDMO and CDMO order books, capacity additions and the hiring outlook across Hyderabad, Bengaluru, Pune, Ahmedabad and Visakhapatnam.

Global lens. North America: the JPM week read-out. What US pharma dealmaking and supply chain de-risking mean for Indian outsourcing partners.

TWO WHITEPAPERS | SPONSOR-OWNED, EDITORIALY LED

WHITEPAPER 1

CRDMO India 2027: Winning Western Programmes in a Supply Chain Reset

How Indian integrated research and manufacturing partners can turn Western de-risking demand into multi-year contracts: the capabilities buyers audit, pricing models and the quality signals that close deals.

WHITEPAPER 2

The R&D Case for Budget 2027-28

An evidence-led brief on the incentives that would move Indian companies from process innovation to new molecule discovery, written for industry bodies and policy teams.

INDUSTRY REPORTS | INDIA FOCUS + INTERNATIONAL FOCUS

INDIA

India CRDMO and CDMO Landscape Report 2027

Capacity, capabilities, client geographies and investment pipelines of India's leading contract research and manufacturing players.

NORTH AMERICA

US Biopharma Outsourcing Outlook 2027

Demand for external development and manufacturing among US sponsors, and the share realistically addressable by India.

TWO SPECIAL NEWSLETTERS

SPECIAL EDITION 1

JPM Week Dispatch

What US dealmakers and investors said about India, filed during the J.P. Morgan Healthcare Conference week.

SPECIAL EDITION 2

CRDMO Capacity Watch

New plants, expansions and hiring across India's contract research and manufacturing hubs to track in 2027.

SPONSORABLE WEBINARS THIS MONTH

W01 Flow Chemistry and Continuous API Manufacturing: From Pilot to Commercial Scale

Technology focus: Continuous flow reactors, process intensification

W02 Faster Tech Transfer: Scientific Data Platforms for CRDMOs

Technology focus: ELN, LIMS and cloud R&D data platforms

Own a whitepaper, report, newsletter or webinar in **January**.

coo@mmactiv.com | communications@mmactiv.com

02

FEBRUARY 2027 Q1 · Policy and Platforms

Bioeconomy and the Policy Engine

BioE3 has named six thematic sectors for India's bioeconomy. February tracks what has actually moved in each of them, and where public ambition is meeting private capacity.

Calendar hooks: BioAsia, Hyderabad (usually February); BioE3 policy milestones

COVER STORY

Where are India's next biomanufacturing hubs headed?

Story focus: Current developments across the six thematic sectors of the BioE3 policy.

India lens. Progress across the six BioE3 thematic sectors, biomanufacturing and Bio-AI hubs, PRIP scheme disbursements, and a side-by-side comparison of state life sciences incentives.

Global lens. Europe: EU pharmaceutical legislation reform and Joint Clinical Assessments under the EU HTA Regulation, and what they change for Indian exporters.

TWO WHITEPAPERS | SPONSOR-OWNED, EDITORIALY LED

WHITEPAPER 1

BioE3 in Motion: From Policy Framework to Operating Biomanufacturing Hubs

Tracks progress on biofoundries, precision fermentation and biomanufacturing hubs, and sets out what private partners need from the next phase.

WHITEPAPER 2

Selling into a Reformed Europe: A Market Access Playbook for Indian Pharma

Practical guidance on EU pharma reform, HTA joint assessments and tender dynamics for Indian generics, biosimilars and specialty exporters.

INDUSTRY REPORTS | INDIA FOCUS + INTERNATIONAL FOCUS

INDIA

State Life Sciences Policy Scorecard 2027

Ranks the major states on incentives, infrastructure, approval speed, talent and ecosystem depth.

EUROPE

Europe Generics and Biosimilars Market Access Report 2027

Pricing, tendering and uptake across key EU markets and the UK, with entry routes for Indian manufacturers.

TWO SPECIAL NEWSLETTERS

SPECIAL EDITION 1

Budget Decoded

A same-week special edition on what Union Budget 2027-28 means for pharma, biotech, diagnostics and research.

SPECIAL EDITION 2

State Policy Tracker

Incentives, new biotech parks and approvals from the states competing for life sciences investment.

SPONSORABLE WEBINARS THIS MONTH

W03 Precision Fermentation at Scale: Bioreactor Strategies for Industrial Biomanufacturing

Technology focus: Fermentation, strain-to-scale-up bioprocessing

W04 Greener Pharma Plants: Energy, Water and Solvent Recovery

Technology focus: Sustainable manufacturing, utilities, recovery systems

Own a whitepaper, report, newsletter or webinar in **February**.

coo@mmactiv.com | communications@mmactiv.com

03

MARCH 2027 Q1 · Policy and Platforms

Biosimilars and Biologics: India's Next Export Engine

Lighter-touch regulatory thinking in the US and steady uptake in Europe are reopening the biosimilar opportunity. March looks at who in India is built to capture it.

Calendar hooks: International Women's Day (8 March); BioSpectrum anniversary; BIO-Europe Spring (March)

COVER STORY

The Second Biosimilar Wave: How Indian developers plan to win the next loss-of-exclusivity cycle

Story focus: The issue also celebrates International Women's Day and the BioSpectrum anniversary.

India lens. Pipelines, manufacturing scale and partnering models of India's biosimilar leaders and emerging challengers.

Global lens. North America: shifting US FDA expectations on comparative efficacy studies and interchangeability, and the payer and PBM dynamics that decide uptake.

TWO WHITEPAPERS | SPONSOR-OWNED, EDITORIALY LED

WHITEPAPER 1

Intensified Bioprocessing for Biosimilars: Lower Cost of Goods at Global Quality

Perfusion, continuous chromatography and single-use strategies that let Indian manufacturers compete on cost without compromising comparability.

WHITEPAPER 2

Comparability First: Building Biosimilar Dossiers Around Analytics

How advanced analytical characterisation can carry more of the regulatory weight as agencies rethink large confirmatory trials.

INDUSTRY REPORTS | INDIA FOCUS + INTERNATIONAL FOCUS

INDIA

India Biosimilars Pipeline Report 2027

A molecule-by-molecule view of Indian biosimilar programmes, target markets, partners and launch windows.

NORTH AMERICA

US Biosimilar Market Access and Interchangeability Outlook

Uptake trends, interchangeable designations, pricing pressure and partnering openings for Indian developers.

TWO SPECIAL NEWSLETTERS

SPECIAL EDITION 1

Biosimilar Launch Radar

The biologics losing exclusivity in the US and Europe, and the Indian developers positioned to launch.

SPECIAL EDITION 2

Bioprocess Tech Brief

Single-use, perfusion and continuous processing updates for biologics manufacturing teams.

SPONSORABLE WEBINARS THIS MONTH

W05 Intensified Upstream: Perfusion and N-1 Strategies for Biosimilars

Technology focus: Perfusion, cell retention, single-use bioreactors

W06 Mass Spectrometry for Biosimilar Comparability

Technology focus: LC-MS characterisation, multi-attribute methods

Own a whitepaper, report, newsletter or webinar in **March**.

coo@mmactiv.com | communications@mmactiv.com

04

APRIL 2027 Q2 · Pipelines and Patients

Vaccines and the National Immunisation Programme

India supplies a large share of the world's vaccines, and its own national immunisation programme is among the largest anywhere. April asks how vaccine makers are strengthening that programme at home.

Calendar hooks: World Health Day (7 April); World Immunization Week (last week of April)

COVER STORY

India's vaccine makers strengthen the National Immunisation Programme

Story focus: The national immunisation programme: coverage, new vaccine introductions and the manufacturers supplying it.

India lens. Vaccines added to the national immunisation programme, supply capacity, new platforms (mRNA, conjugate, VLP) and the WHO prequalification pipeline.

Global lens. Europe: HERA, CEPI-backed manufacturing networks and European preparedness procurement, and where Indian manufacturers fit.

TWO WHITEPAPERS | SPONSOR-OWNED, EDITORIALY LED

WHITEPAPER 1

Rapid-Response Vaccine Platforms: Building mRNA and LNP Capability in India

The technology, supply chain and regulatory building blocks for a 100-day-ready vaccine manufacturing base.

WHITEPAPER 2

Fill-Finish at Global Standard: Annex 1 Readiness for Indian Sterile Manufacturers

Contamination control strategies, barrier technology and primary packaging choices that satisfy EU and US inspectors.

INDUSTRY REPORTS | INDIA FOCUS + INTERNATIONAL FOCUS

INDIA

India Vaccine Manufacturing and Export Report 2027

Installed capacity, platform mix, prequalified products and export destinations of Indian vaccine makers.

EUROPE

Europe Pandemic Preparedness and Vaccine Procurement Report

Funding flows, reserve-capacity contracts and partnering routes across EU preparedness programmes.

TWO SPECIAL NEWSLETTERS

SPECIAL EDITION 1

Vaccine Supply Watch

Prequalification, capacity and export updates from India's vaccine makers, published for World Immunization Week.

SPECIAL EDITION 2

Sterile Manufacturing Brief

Annex 1 compliance, fill-finish technology and contamination control practice from the plant floor.

SPONSORABLE WEBINARS THIS MONTH

W07 **mRNA and LNP Formulation: Building Platform Capability**
Technology focus: IVT mRNA, lipid nanoparticles, microfluidic mixing

W08 **Annex 1 Contamination Control Strategy for Aseptic Fill-Finish**
Technology focus: Isolators, RABS, cleanroom disinfection

Own a whitepaper, report, newsletter or webinar in **April**.

coo@mmactiv.com | communications@mmactiv.com

05

MAY 2027 Q2 · Pipelines and Patients

Clinical Research India: Speed, Scale and Site Quality

With ICH E6(R3) in force in major markets and global sponsors widening their site networks, May examines whether India can become a first-choice trial destination.

Calendar hooks: International Clinical Trials Day (20 May); ASCO Annual Meeting (late May to early June)

COVER STORY

First Choice or Fallback? The state of India's clinical trial competitiveness

Story focus: Includes a BioSpectrum India editorial survey on India's growing role in global clinical trials.

India lens. Approval timelines, site networks, patient recruitment, oncology and rare disease trials, and CRO capacity.

Global lens. North America: how US sponsors choose Asia-Pacific trial sites, diversity expectations and data acceptability.

TWO WHITEPAPERS | SPONSOR-OWNED, EDITORIALY LED

WHITEPAPER 1

ICH E6(R3) in Practice: Risk-Based Quality Management for Indian Trial Sites

What the revised GCP means for sponsors, CROs and investigators, with a practical readiness checklist.

WHITEPAPER 2

Hybrid and Decentralised Trials in India: Technology, Data Integrity and Patient Access

The tech stack, logistics and consent models that make remote trial elements work at Indian scale.

INDUSTRY REPORTS | INDIA FOCUS + INTERNATIONAL FOCUS

INDIA

India Clinical Trials Landscape Report 2027

Registered trials by phase, therapy area, sponsor type and geography, with site and CRO benchmarks.

NORTH AMERICA

US Sponsor Site Selection Survey: Asia-Pacific and India

A survey-led view of how US biotechs and pharma rank global trial destinations and why.

TWO SPECIAL NEWSLETTERS

SPECIAL EDITION 1

Trial Tracker India

New trial approvals, site network expansions and CRO moves, published on International Clinical Trials Day.

SPECIAL EDITION 2

ASCO Preview

Indian and global oncology data to watch ahead of the ASCO Annual Meeting.

SPONSORABLE WEBINARS THIS MONTH

W09 Risk-Based Quality Management and eClinical Under ICH E6(R3)

Technology focus: RBQM, EDC, eConsent, central monitoring

W10 Real-World Evidence for Indian Market Access and Label Expansion

Technology focus: RWD platforms, analytics, evidence generation

Own a whitepaper, report, newsletter or webinar in **May**.

coo@mmactiv.com | communications@mmactiv.com

06

JUNE 2027 Q2 · Pipelines and Patients

Made-in-India Innovation: From Molecule to Global Deal

Indian companies are now licensing novel assets and technologies to Western partners. June, timed to the BIO International Convention, tracks the innovators and the deals.

Calendar hooks: BIO International Convention (June, US); mid-year deal review

COVER STORY

Discovered at Home, Licensed Abroad: The Indian innovation the West is paying for

Story focus: Global licensing deals and partnerships originating in India across verticals, not limited to pharma.

India lens. Licensing deals and partnerships across pharma, biotech, diagnostics, medtech and platform technologies, start-up funding, and the role of AI-first discovery companies.

Global lens. North America: the US biotech funding climate and licensing appetite, and how Indian assets are valued at the table.

TWO WHITEPAPERS | SPONSOR-OWNED, EDITORIALY LED

WHITEPAPER 1

Out-Licensing from India: Structuring Deals Western Partners Will Sign

Data packages, IP positioning, deal terms and alliance governance, drawn from recent India-origin transactions.

WHITEPAPER 2

AI in Drug Discovery: From Platform Claims to Validated Pipelines

Where AI is measurably shortening discovery timelines, and the data, compute and wet-lab infrastructure it needs.

INDUSTRY REPORTS | INDIA FOCUS + INTERNATIONAL FOCUS

INDIA

India BioPharma Deals and Out-Licensing Tracker: H1 2027

Every disclosed licensing, partnership and funding deal involving Indian biopharma in the first half of 2027.

NORTH AMERICA

North America Biotech Funding and Licensing Report: H1 2027

Venture, IPO and licensing activity in the US and Canada, with the therapy areas and modalities attracting capital.

TWO SPECIAL NEWSLETTERS

SPECIAL EDITION 1

India at BIO 2027

A convention special on Indian delegations, partnering meetings and announcements at the BIO International Convention.

SPECIAL EDITION 2

Deal Desk: H1 2027

India's licensing, partnership and funding round-up for the first half of the year.

SPONSORABLE WEBINARS THIS MONTH

W11 AI-Driven Target Discovery and Molecular Design

Technology focus: Generative chemistry, GPU compute, knowledge graphs

W12 Automated Liquid Handling and High-Throughput Screening

Technology focus: Lab automation, robotics, assay miniaturisation

Own a whitepaper, report, newsletter or webinar in **June**.

coo@mmactiv.com | communications@mmactiv.com

07

JULY 2027 Q3 · Precision and Production

Diagnostics, Genomics and Precision Medicine

From GenomeIndia to point-of-care molecular testing in district hospitals, diagnostics is where Indian science reaches patients fastest. July follows the test from lab to clinic.

Calendar hooks: ADLM Annual Meeting (typically late July, US)

COVER STORY

The Test Comes First: How Indian diagnostics and genomics companies are shaping precision care

India lens. GenomeIndia follow-on programmes, NGS adoption in oncology and rare disease, and Indian point-of-care molecular platforms.

Global lens. Europe: the extended IVDR transition, notified body capacity and what Indian IVD makers need to enter the EU market.

TWO WHITEPAPERS | SPONSOR-OWNED, EDITORIALY LED

WHITEPAPER 1

Population Genomics to Clinical Practice: Lessons from GenomeIndia

How population-scale data can translate into screening, pharmacogenomics and faster rare disease diagnosis.

WHITEPAPER 2

Molecular Diagnostics Beyond the Metros: Point-of-Care Platforms for Tier-2 and Tier-3 India

Device, assay and reimbursement models that make molecular testing viable outside big-city labs.

INDUSTRY REPORTS | INDIA FOCUS + INTERNATIONAL FOCUS

INDIA

India IVD and Genomics Market Report 2027

Market size, segment growth, domestic versus imported share, and the genomics service landscape.

EUROPE

Europe IVDR Readiness and Market Entry Report

Certification status, notified body bottlenecks and practical entry routes for Indian IVD exporters.

TWO SPECIAL NEWSLETTERS

SPECIAL EDITION 1

Genomics Brief

Sequencing programmes, precision medicine launches and population genomics updates from India and abroad.

SPECIAL EDITION 2

Lab to Market

IVD launches, approvals and point-of-care diagnostics news for laboratory and hospital buyers.

SPONSORABLE WEBINARS THIS MONTH

W13 **NGS for Oncology and Rare Disease Diagnosis**
Technology focus: Sequencing platforms, panels, bioinformatics

W14 **Point-of-Care Molecular Testing Beyond the Metros**
Technology focus: Portable PCR, cartridge assays, connectivity

Own a whitepaper, report, newsletter or webinar in **July**.

coo@mmactiv.com | communications@mmactiv.com

08

AUGUST 2027 Q3 · Precision and Production

Biologics Manufacturing and Digitisation

Independence Day month is the right moment to audit Make in India on the factory floor. August looks at how digital tools are raising quality and output in Indian biologics manufacturing.

Calendar hooks: Independence Day (15 August); US tariff and onshoring developments

COVER STORY

The Quality Dividend: How digital tools are reshaping Indian biologics manufacturing

Story focus: Biologics manufacturing and the digital tools behind it.

India lens. Biologics capacity, digital tools across upstream, downstream and quality control, automation investments and the smart factory business case.

Global lens. North America: US onshoring incentives, tariffs and FDA inspection trends, and the new cost equation for Indian API and generics exporters.

TWO WHITEPAPERS | SPONSOR-OWNED, EDITORIALY LED

WHITEPAPER 1

Revised Schedule M: Closing the GMP Gap for Mid-Sized Manufacturers

Common gaps, upgrade costs, financing routes and technology shortcuts for MSME units.

WHITEPAPER 2

Digital Twins and PAT: Data-Driven Control for Pharma and Bioprocessing

How process analytical technology and simulation cut batch failures and speed up tech transfer.

INDUSTRY REPORTS | INDIA FOCUS + INTERNATIONAL FOCUS

INDIA

India Pharma Quality and Compliance Report 2027

Inspection outcomes, warning letters, remediation timelines and investment in quality systems.

NORTH AMERICA

US Onshoring and Tariff Impact Report for Indian Exporters

Where US policy raises costs, where it opens doors, and how Indian exporters are restructuring to respond.

TWO SPECIAL NEWSLETTERS

SPECIAL EDITION 1

Quality Watch

Inspection outcomes, warning letters, remediation stories and Revised Schedule M progress.

SPECIAL EDITION 2

Smart Plant Brief

Automation, digital twins and process analytics in Indian pharma and biologics plants.

SPONSORABLE WEBINARS THIS MONTH

W15 Digital Twins and PAT for Right-First-Time Batches

Technology focus: Process analytics, modelling, MES integration

W16 Data Integrity and Computerised System Validation for Revised Schedule M

Technology focus: CSV and CSA, audit trails, QMS software

Own a whitepaper, report, newsletter or webinar in **August**.

coo@mmactiv.com | communications@mmactiv.com

09

SEPTEMBER 2027 Q3 · Precision and Production

Cell and Gene Therapy: Addressing the Challenges

India has shown that CAR-T can be made at a fraction of Western prices. September looks in depth at the long-term challenges of scaling cell and gene therapies, from manufacturing to follow-up.

Calendar hooks: Builds on BioSpectrum India's CGT Global Convergence series; run-up to ESGCT Congress (typically October, Europe)

COVER STORY

The Challenging Cure: India's advanced therapy makers and the race to scale

Story focus: The long-term challenges facing cell and gene therapy.

India lens. Manufacturing cost, vector supply, long-term patient follow-up, reimbursement and regulatory pathways, alongside CAR-T and gene therapy pipelines.

Global lens. Europe: ATMP regulation, the hospital exemption, and cross-border partnering opportunities with European developers.

TWO WHITEPAPERS | SPONSOR-OWNED, EDITORIALY LED

WHITEPAPER 1

Point-of-Care CAR-T: Decentralised Manufacturing Models for India

Closed, automated systems, quality release and hospital partnership models that lower the cost per patient.

WHITEPAPER 2

Viral Vector Supply for India: Build, Buy or Partner

Capacity, cost and regulatory trade-offs across in-house, CDMO and partnership routes to vector supply.

INDUSTRY REPORTS | INDIA FOCUS + INTERNATIONAL FOCUS

INDIA

India Cell and Gene Therapy Pipeline Report 2027

Programmes by modality, indication and stage, with manufacturing capacity and clinical site maps.

EUROPE

Europe ATMP Market and Partnering Report

Approvals, reimbursement, hospital exemption use and partnering routes for Indian developers.

TWO SPECIAL NEWSLETTERS

SPECIAL EDITION 1

CGT Special Edition

CAR-T, gene therapy and RNA therapeutics updates from Indian developers, hospitals and manufacturers.

SPECIAL EDITION 2

ATMP Europe Brief

European advanced therapy regulation, reimbursement and partnering news for Indian developers.

SPONSORABLE WEBINARS THIS MONTH

W17 Closed, Automated CAR-T Manufacturing at the Point of Care

Technology focus: Automated cell processing, closed systems

W18 Viral Vector Production and Analytics

Technology focus: AAV and lentiviral upstream, purification, titre analytics

Own a whitepaper, report, newsletter or webinar in **September**.

coo@mmactiv.com | communications@mmactiv.com

10

OCTOBER 2027 Q4 · Power Shifts

Rare Cancers and the Access Question

Innovative therapies for rare cancers are reaching India faster, but price and access still decide outcomes. October looks at who is closing the gap.

Calendar hooks: ESMO Congress (October, Europe); Breast Cancer Awareness Month

COVER STORY

Access Is the Therapy: Bringing innovative rare cancer therapies to Indian patients

Story focus: Rare cancers.

India lens. Launch timelines for rare cancer therapies, diagnosis, patient assistance programmes, local manufacturing of complex oncology products, and the National Policy for Rare Diseases.

Global lens. North America and Europe: drug pricing reform on both sides of the Atlantic, and how it reshapes launch sequencing into India.

TWO WHITEPAPERS | SPONSOR-OWNED, EDITORIALY LED

WHITEPAPER 1

Access Models for Innovative Oncology in India

Pricing, patient support, insurance and diagnostics-led models that widen access to new cancer therapies.

WHITEPAPER 2

ADCs and Complex Oncology Manufacturing: India's Opportunity

The capabilities, containment and conjugation chemistry Indian CDMOs need to serve the antibody-drug conjugate boom.

INDUSTRY REPORTS | INDIA FOCUS + INTERNATIONAL FOCUS

INDIA

India Oncology and Rare Disease Access Report 2027

Launch lag, pricing, reimbursement coverage and patient programme reach for innovative therapies.

NORTH AMERICA + EUROPE

Transatlantic Drug Pricing Reform Report

US pricing measures alongside European HTA and pricing trends, with implications for global launch sequencing.

TWO SPECIAL NEWSLETTERS

SPECIAL EDITION 1

ESMO Special

Indian and global oncology highlights from the ESMO Congress, with access implications for India.

SPECIAL EDITION 2

Access Watch

Drug pricing, insurance cover and patient programmes shaping access to innovative medicines in India.

SPONSORABLE WEBINARS THIS MONTH

W19 ADC Manufacturing: Conjugation, Containment and Analytics

Technology focus: Bioconjugation, high-potency containment, DAR analytics

W20 Spatial Biology and Multiplex Imaging for Oncology Biomarkers

Technology focus: Spatial transcriptomics, multiplex IHC

Own a whitepaper, report, newsletter or webinar in **October**.

coo@mmactiv.com | communications@mmactiv.com

11

NOVEMBER 2027 Q4 · Power Shifts

Indian Pharma in the Western Supply Chain Reset

US biosecurity restrictions and European security-of-supply rules are redrawing sourcing maps. November, the CPHI India month, tracks India's chance to become the default alternative.

Calendar hooks: CPHI and PMEC India (typically late November); BIO-Europe (November)

COVER STORY

The Default Alternative? India's API and KSM makers in the great pharma sourcing reset

Story focus: The pharma supply chain.

India lens. PLI outcomes for KSMs and APIs, bulk drug parks, CDMO capacity and the logistics backbone for biologics exports.

Global lens. Europe: the EU Critical Medicines Act and security-of-supply sourcing, plus the US BIOSECURE landscape for biotech buyers.

TWO WHITEPAPERS | SPONSOR-OWNED, EDITORIALY LED

WHITEPAPER 1

China+1 to India First: De-Risking API and KSM Supply for US and EU Buyers

A buyer-facing guide to Indian capacity, quality track record and dual-sourcing models.

WHITEPAPER 2

Temperature-Controlled Logistics for Biologics and Advanced Therapies

Cold chain, cryogenic and last-mile solutions that protect product integrity from Indian plants to Western patients.

INDUSTRY REPORTS | INDIA FOCUS + INTERNATIONAL FOCUS

INDIA

India API and KSM Self-Reliance Report 2027

PLI project status, bulk drug park progress and remaining import dependence by molecule class.

EUROPE

Europe Security-of-Supply and Sourcing Report

How EU buyers are re-shoring and diversifying critical medicine supply, and the share open to Indian suppliers.

TWO SPECIAL NEWSLETTERS

SPECIAL EDITION 1

CPHI India Special

Show preview and exhibitor highlights for CPHI and PMEC India, sent to visitors before they walk the floor.

SPECIAL EDITION 2

Supply Chain Monitor

BIOSECURE, EU security-of-supply rules and API sourcing trends affecting Indian suppliers.

SPONSORABLE WEBINARS THIS MONTH

W21 Cold Chain and Cryogenic Logistics for Biologics and CGT Exports

Technology focus: Temperature-controlled packaging, cryo shipping, tracking

W22 Container Closure Integrity and Primary Packaging for Injectables

Technology focus: Vials, prefilled syringes, CCI testing

Own a whitepaper, report, newsletter or webinar in **November**.

coo@mmactiv.com | communications@mmactiv.com

12

DECEMBER 2027 Q4 · Power Shifts

The Road to 2028: AI, Talent and the Leaders of 2027

We close the year by naming the people and companies who moved the industry, and by asking what AI, data and talent will demand of Indian life sciences in 2028.

Calendar hooks: ASH Annual Meeting (December, US); year-end reviews

COVER STORY

The Year That Was, the Year Ahead: BioSpectrum India's leaders of 2027 and the 2028 agenda

India lens. Year-end scorecard, leaders' honours, and AI adoption across R&D, manufacturing, regulatory and commercial functions.

Global lens. North America and Europe: the 2028 outlook for Western pharma demand, pricing and partnering, and what it means for Indian strategy.

TWO WHITEPAPERS | SPONSOR-OWNED, EDITORIALY LED

WHITEPAPER 1

AI Across the Life Sciences Value Chain: A 2028 Readiness Playbook

Where AI is paying back today, from discovery to pharmacovigilance, with governance and GxP validation guidance.

WHITEPAPER 2

Talent 2028: Skilling India's Bioeconomy Workforce

Skills gaps in bioprocessing, regulatory science, data and CGT, and the industry-academia models that close them.

INDUSTRY REPORTS | INDIA FOCUS + INTERNATIONAL FOCUS

INDIA

BioSpectrum India Annual Industry Scorecard 2027

Revenue, R&D, deals, approvals and capacity across the Indian biopharma, diagnostics and bioservices sectors.

NORTH AMERICA + EUROPE

Western Pharma Outlook 2028: Demand, Pricing and Partnering

What US and European pharma will buy, pay and partner for in 2028, and where Indian companies can win.

TWO SPECIAL NEWSLETTERS

SPECIAL EDITION 1

Year in Review 2027

The deals, approvals, policies and people that defined Indian life sciences in 2027.

SPECIAL EDITION 2

2028 Outlook

What AI, talent and Western demand mean for Indian life sciences strategy in the year ahead.

SPONSORABLE WEBINARS THIS MONTH

W23 **Generative AI for Regulatory Writing and Pharmacovigilance**
Technology focus: LLM-assisted authoring, case processing automation

W24 **Cloud, Cybersecurity and GxP Compliance for Life Sciences Data**
Technology focus: Validated cloud, zero-trust security, data residency

Own a whitepaper, report, newsletter or webinar in **December**.

coo@mmactiv.com | communications@mmactiv.com

WEBINAR BANK

24 technology webinars you can sponsor

Each 60-minute webinar brings together one sponsor speaker, one independent Indian practitioner and a BioSpectrum India moderator. Slots follow the monthly themes, and any topic can move to fit your launch calendar or be replaced with a custom brief.

#	SLOT	WEBINAR TOPIC	TECHNOLOGY FOCUS
W01	Jan 2027	Flow Chemistry and Continuous API Manufacturing: From Pilot to Commercial Scale	Continuous flow reactors, process intensification
W02	Jan 2027	Faster Tech Transfer: Scientific Data Platforms for CRDMOs	ELN, LIMS and cloud R&D data platforms
W03	Feb 2027	Precision Fermentation at Scale: Bioreactor Strategies for Industrial Biomanufacturing	Fermentation, strain-to-scale-up bioprocessing
W04	Feb 2027	Greener Pharma Plants: Energy, Water and Solvent Recovery	Sustainable manufacturing, utilities, recovery systems
W05	Mar 2027	Intensified Upstream: Perfusion and N-1 Strategies for Biosimilars	Perfusion, cell retention, single-use bioreactors
W06	Mar 2027	Mass Spectrometry for Biosimilar Comparability	LC-MS characterisation, multi-attribute methods
W07	Apr 2027	mRNA and LNP Formulation: Building Platform Capability	IVT mRNA, lipid nanoparticles, microfluidic mixing
W08	Apr 2027	Annex 1 Contamination Control Strategy for Aseptic Fill-Finish	Isolators, RABS, cleanroom disinfection
W09	May 2027	Risk-Based Quality Management and eClinical Under ICH E6(R3)	RBQM, EDC, eConsent, central monitoring
W10	May 2027	Real-World Evidence for Indian Market Access and Label Expansion	RWD platforms, analytics, evidence generation
W11	Jun 2027	AI-Driven Target Discovery and Molecular Design	Generative chemistry, GPU compute, knowledge graphs
W12	Jun 2027	Automated Liquid Handling and High-Throughput Screening	Lab automation, robotics, assay miniaturisation
W13	Jul 2027	NGS for Oncology and Rare Disease Diagnosis	Sequencing platforms, panels, bioinformatics
W14	Jul 2027	Point-of-Care Molecular Testing Beyond the Metros	Portable PCR, cartridge assays, connectivity
W15	Aug 2027	Digital Twins and PAT for Right-First-Time Batches	Process analytics, modelling, MES integration
W16	Aug 2027	Data Integrity and Computerised System Validation for Revised Schedule M	CSV and CSA, audit trails, QMS software
W17	Sep 2027	Closed, Automated CAR-T Manufacturing at the Point of Care	Automated cell processing, closed systems
W18	Sep 2027	Viral Vector Production and Analytics	AAV and lentiviral upstream, purification, titre analytics
W19	Oct 2027	ADC Manufacturing: Conjugation, Containment and Analytics	Bioconjugation, high-potency containment, DAR analytics
W20	Oct 2027	Spatial Biology and Multiplex Imaging for Oncology Biomarkers	Spatial transcriptomics, multiplex IHC
W21	Nov 2027	Cold Chain and Cryogenic Logistics for Biologics and CGT Exports	Temperature-controlled packaging, cryo shipping, tracking
W22	Nov 2027	Container Closure Integrity and Primary Packaging for Injectables	Vials, prefilled syringes, CCI testing
W23	Dec 2027	Generative AI for Regulatory Writing and Pharmacovigilance	LLM-assisted authoring, case processing automation
W24	Dec 2027	Cloud, Cybersecurity and GxP Compliance for Life Sciences Data	Validated cloud, zero-trust security, data residency

PARTNER WITH BIOSPECTRUM INDIA

Ways to own a month

Every format can be booked on its own or combined into a theme-month or full-year programme. Tell us your launch calendar and target audience, and we will map the right months for you.

Whitepaper sponsorship	Own one of the month's two whitepapers: co-developed outline, editorially led writing, gated download and qualified lead delivery.
Industry report partnership	Presenting partner on the India or global report, with a data sidebar, a launch webinar and distribution to the BioSpectrum India audience.
Special newsletter sponsorship	Exclusive presenting partner of a themed special edition: masthead branding, a native content slot and a banner, sent to the full subscriber base.
Webinar sponsorship	Choose a topic from the webinar bank or brief a custom one. Includes promotion across web, newsletter and EDM, registrant data and on-demand hosting.
Theme-month package	Print and digital display, a sponsored feature alongside the cover story, social amplification and a dedicated EDM in the month of your choice.

PARTNERSHIP AND EDITORIAL ENQUIRIES

coo@mmactiv.com
communications@mmactiv.com

www.biospectrumindia.com

MM Activ Sci-Tech Communications Pvt. Ltd., "Ashirwad", 1st Floor, 36/A/2, S. No. 270, Pallod Farms, Baner Road, Pune 411 045, India

Themes, report titles and webinar slots may be refined as the 2027 policy and industry calendar firms up. Event references are indicative.



the business of Bio & Health Sciences
BioSpectrum

24 years of leveraging the business of Bio & Health Sciences
www.biospectrumindia.com